原发性肝癌（HCC）是世界上最常见恶性肿瘤之一，已成为危害人类健康的重要因素。探索HCC有效的防治策略及效应机制是目前研究的热点。外泌体是由细胞内形成并分泌到细胞外的囊泡小体，是细胞间通讯和信息传递的新模式。研究表明肝癌细胞通过释放外泌体促进癌基因、功能蛋白分子、肿瘤相关RNAs的转移而对肿瘤的发生发展、侵袭转移产生影响。本课题组前期研究发现癌痛消中药复方治疗HCC能使肿瘤体积缩小并明显降低患者AFP水平，其机制与促进肝癌细胞凋亡和提高免疫功能有关。本研究拟用癌痛消方含药血清体外干预癌活性肝细胞系和非癌活性肝细胞系，检测实验细胞释放外泌体的含量变化、并应用蛋白质组学、离子激流测序、流式细胞技术等方法观察含药血清通过调节实验细胞来源的外泌体蛋白分子、RNAs对肝癌细胞发生发展和侵袭转移能力、以及对293T细胞的影响，探讨癌痛消方通过外泌体调节免疫功能的效应靶点，以及抗HCC的细胞和分子机制。

HCC is one of the popular caner in the world and because of limitation of the therapeutic strategies of HCC and the risk of the disease，exploring the new targets and the strategies is becoming hotspot and medical difficulty. Data showed that exosome can regulate immune activity via regulating the expression profile of the proteins and RNAs. Previously we found that the efficiency of the Chinese medicine Aixiaokeli on treating HCC is 88.89% and it showed a great effect on apoptosis and the inflammatory factors. In order to analysis the targets and the effect of aixiaokeli，we will use the cell lines and the patients to examine the effect of Aixiaokeli, we will separate the exosomes and use Proteomics，RNAs examination and the FCM flow cytometer. This program will provide a new possible the clinical and the foundation research